Manipal Health Enterprises IPO (29-31 July) Analysis
- Jul 26
- 14 min read
Updated: 5 days ago
IPO Analysis | NSE and BSE Main Board | 100% Book Built Offer (Fresh Issue and Offer for Sale) | Regulation 6(1)
Based on Draft Red Herring Prospectus dated March 23, 2026 | Multispecialty Hospital Network | Bengaluru, Karnataka
STATUS: DRHP FILED | Fresh Issue: up to Rs.80,000 Million | Offer for Sale: up to 43,227,668 Shares | Regulation 6(1) | NSE and BSE Main Board | Pre-SEBI Observation Stage | Largest Hospital Network by Bed Capacity in India | 48 Hospitals, 12,367 Beds (Pro Forma) |
Manipal Health Enterprises Limited operates 'Manipal Hospitals', a pan-India network of multispecialty hospitals headquartered in Bengaluru, Karnataka. The company was incorporated in February 2010 and converted to a public limited company in December 2025. Its registered and corporate office is at The Annexe, #98/2, Rustom Bagh, HAL Airport Road, Bengaluru 560017, Karnataka. Its website is www.manipalhospitals.com. Its CIN is U85110KA2010PLC052540.
The Promoters are Dr. Ranjan Ramdas Pai, Manipal Global Health Services, MEMG International Ltd, Kangto Investments Pte Ltd, Imperius Healthcare Investments Pte Ltd, and Kabru Investments Pte Ltd. The company's legacy traces to the Pai family: Dr. T. M. A. Pai, a founder of Syndicate Bank and Kasturba Medical College in Manipal (one of India's first private medical colleges) and a 1972 Padma Shri recipient, and Dr. Ramdas Pai, a 2011 Padma Bhushan recipient.
According to the CRISIL Report commissioned for this Offer, Manipal Hospitals is India's largest pan-India multispecialty hospital network by bed capacity and the second-largest hospital chain by number of hospitals, as of September 30, 2025. As of that date, the company operated 38 hospitals with 10,761 licensed beds on an actual (standalone Restated) basis; on a pro forma basis giving effect to the recent Sahyadri acquisition, this rises to 48 hospitals with 12,367 licensed beds across 14 states and union territories, the widest footprint among private hospital chains in India.
In November 2025, the company opened its 49th hospital in Bengaluru, taking licensed bed capacity to 12,631 by December 31, 2025. The company reported the second-highest revenue from operations (Rs.92,635.56 million, pro forma) and third-highest revenue (Rs.82,422.50 million, actual) among private hospital chains in India for Fiscal 2025, per the CRISIL Report.
The company leads by bed capacity in its three key regions: Karnataka (18 hospitals, 6,040 licensed beds), Maharashtra and Goa (13 hospitals, 2,188 licensed beds, largest on a pro forma basis following the Sahyadri acquisition), and Eastern India spanning West Bengal, Odisha, Jharkhand and Sikkim (10 hospitals, 2,887 licensed beds). It is the only private hospital chain in India leading in three metro markets simultaneously: Bengaluru, Kolkata, and Pune.
The company focuses on high-acuity tertiary and quaternary care across Cardiac sciences, Oncology, Neurosciences, Gastro sciences, Orthopedics, and Renal sciences (collectively 'CONGO-R'), which contributed 64.08% of gross inpatient revenue in H1 FY2026. Growth has combined organic expansion with a track record of acquisitions, including Columbia Asia and Vikram Hospital (2021), AMRI Hospital (September 2023), Medica Synergie (July 2024), and, most recently, the Sahyadri Group (October to December 2025), adding 10 hospitals and 1,606 licensed beds in Maharashtra.
The company's shareholder base includes global institutional investors such as indirect subsidiaries of Temasek Holdings, TPG SG Magazine Pte. Ltd., and Novo Holdings Invest Asia A/S. Company Secretary and Compliance Officer is Sathish Kolar Ramamoorthy. The company's financial year ends March 31.
Key Basics
This Offer is a 100% Book Built Offer combining a Fresh Issue of up to Rs.80,000 Million (Rs.8,000 Crore) by the Company, by far the largest Fresh Issue size in this report series, with an Offer for Sale of up to 43,227,668 Equity Shares by 7 Selling Shareholders. The DRHP is dated March 23, 2026 and is at the pre-SEBI observation stage.
The Issue is made under Regulation 6(1) of SEBI ICDR Regulations, listing on both NSE and BSE, and is being led by a seven-bank underwriting syndicate reflecting the scale of the transaction. All [TBD] items including Price Band, bid dates and final share counts remain undetermined.
Document Type | Draft Red Herring Prospectus (DRHP) dated March 23, 2026. Pre-SEBI observation stage. All [TBD] items to be finalised at RHP stage. |
Issue Structure | 100% Book Built Offer comprising a Fresh Issue of up to Rs.80,000 Million (share count undetermined) and an Offer for Sale of up to 43,227,668 Equity Shares across 7 Selling Shareholders. Face value Rs.2 per share. |
Face Value | Rs.2 per Equity Share, following a 5:1 sub-division (from Rs.10 to Rs.2) during Fiscal 2025 and a 2:1 bonus issue during H1 FY2026. |
Selling Shareholders | Imperius Healthcare Investments Pte. Ltd. (Promoter Selling Shareholder, up to 21,617,723 shares, WACA Rs.68.73); Manipal Education and Medical Group India Private Limited (Promoter Group Selling Shareholder, up to 13,584,004 shares, WACA Rs.102.56); and 5 Investor Selling Shareholders (TPG SG Magazine, Seventy Second Investment Company, Ammar Sdn Bhd, Novo Holdings Invest Asia, Phoenix Bear Investments), together up to 8,025,941 shares at WACAs ranging from Rs.351.81 to Rs.355.66. |
Possible Pre-IPO Placement | Up to Rs.16,000 Million (20% of Fresh Issue size) may be raised prior to RHP filing at the Board's discretion; if completed, this amount reduces the Fresh Issue size. |
Promoters | Dr. Ranjan Ramdas Pai, Manipal Global Health Services, MEMG International Ltd, Kangto Investments Pte Ltd, Imperius Healthcare Investments Pte Ltd, and Kabru Investments Pte Ltd. |
Eligibility | Regulation 6(1) of SEBI ICDR Regulations, the standard main board profitability-based eligibility route. |
Listing Exchanges | NSE and BSE. Designated Stock Exchange: [TBD]. In-principle approvals received (letter dates [TBD]). |
BRLMs | Kotak Mahindra Capital Company Limited; Axis Capital Limited; Goldman Sachs (India) Securities Private Limited; Jefferies India Private Limited; J.P. Morgan India Private Limited; UBS Securities India Private Limited; and DBS Bank India Limited (restricted to a marketing-only role, see Section 6). |
Registrar | KFin Technologies Limited. Contact: M. Murali Krishna. |
Bid/Issue Dates | All dates (including Price Band) to be announced after SEBI observations and RHP filing. |
Listed Peers | Three listed peers: Apollo Hospitals Enterprise Limited, Fortis Healthcare Limited, and Max Healthcare Institute Limited. Industry P/E: highest 87.63x, lowest 73.23x, average 80.33x. |
The Offer for Sale here spans a genuinely diverse set of sellers, from the Promoter Selling Shareholder and a Promoter Group entity to five separate global institutional investors (including entities associated with TPG and Novo Holdings), each with a different Weighted Average Cost of Acquisition ranging from Rs.68.73 to Rs.355.66 per share, reflecting entry at different funding rounds over more than a decade of private ownership.
One notable governance disclosure: DBS Bank India Limited is named as a Book Running Lead Manager, but its parent, DBS Bank Limited, is also one of the five debenture holders being repaid using this very IPO's Fresh Issue proceeds (see Object 1 in Section 3). DBS Bank India Limited has accordingly been restricted to a marketing-only role in the Offer under SEBI's conflict-of-interest regulations, a disclosed and regulated arrangement rather than a concealed one, but worth flagging given the scale of the repayment involved.
How Will the IPO Money Be Used?
This is a combined Fresh Issue and Offer for Sale; only the Fresh Issue component (up to Rs.80,000 Million) accrues to the Company. The Offer for Sale proceeds go entirely to the 7 Selling Shareholders, and the Company receives no benefit from that portion.
Object | Amount (Rs. Mn) | Details |
Repayment of MHPL Acquisition NCDs | 53,780.00 | Redemption of Rs.53,100 Million of listed non-convertible debentures issued in September 2025 by subsidiary Manipal Hospitals Private Limited (MHPL), which funded the first two tranches of the Sahyadri Acquisition. These NCDs carry a mandatory prepayment clause triggered by this IPO's listing. Constitutes 50.36% of total consolidated outstanding borrowings (Rs.106,127.84 Mn as of January 31, 2026). |
Sahyadri Minority Stake Acquisition | 5,740.00 | Base consideration for the third and final tranche (9.84%) of Sahyadri Hospitals Private Limited (SHPL), due on or before December 1, 2026, taking MHPL's aggregate stake in SHPL to 99.86%. Could rise to up to Rs.6,956.79 Million if the Sahyadri Group's LTM EBITDA reaches Rs.4,000 Million before completion. |
General Corporate Purposes | [TBD] | Capped at 25% of Gross Proceeds. Exact amount to be finalised upon determination of the Offer Price. |
TOTAL FRESH ISSUE | 80,000.00 | Identified specific objects total Rs.59,520.00 Million (74.4% of the Fresh Issue), both tied to the recent Sahyadri Acquisition. None of the Objects have been appraised by a bank or financial institution. |
This Fresh Issue is, in substance, primarily a financing and deleveraging event tied to a single transaction: the acquisition of the Sahyadri Group (Sahyadri Hospitals, Sahyadri Karad Hospitals, Saideep Healthcare and Research, and Surya Hospitals), completed in two tranches between October and December 2025 for an aggregate consideration of approximately Rs.51,709.83 Million and funded via a Rs.53,100 Million bridge issuance of non-convertible debentures by subsidiary MHPL.
Object 1, redeeming those NCDs, alone accounts for 67.2% of the entire Rs.80,000 Million Fresh Issue, and Object 2, completing the acquisition's third and final tranche, adds a further 7.2%, so nearly three-quarters of this very large Fresh Issue is earmarked to repay recent acquisition debt and finish buying out minority shareholders in an asset acquired only months before this DRHP was filed, rather than to fund new hospitals or expansion capex directly.
This is a common and reasonable structure for large PE-backed acquisitions ahead of an IPO, but it does mean the growth story investors are buying into (see Section 4) already reflects an acquisition whose debt this IPO exists substantially to clean up. As with most DRHP-stage filings, the General Corporate Purposes component is capped only as a percentage (25% of Gross Proceeds) rather than an absolute amount.
Financial Performance
Note: All figures in Rs. Million unless stated; Rs. Crore equivalents provided for Revenue and PAT. Financial periods: six months ended September 30, 2025 (H1 FY2026, stub, not annualised, Restated Consolidated basis, i.e. actual, not pro forma); Fiscal 2025, Fiscal 2024 and Fiscal 2023 (years ended March 31, Restated Consolidated basis). *H1 FY2026 RoNW is not annualised.
Revenue, EBITDA, and Profitability
Metric | H1 FY26 (Rs. Mn) | FY2025 (Rs. Mn) | FY2024 (Rs. Mn) | FY2023 (Rs. Mn) |
Revenue from Operations | 47,130.53 | 82,422.50 | 61,716.32 | 48,396.10 |
Revenue (Rs. Crore) | Rs.4,713.1 Cr | Rs.8,242.3 Cr | Rs.6,171.6 Cr | Rs.4,839.6 Cr |
Revenue Growth % YoY | N/A (H1 stub) | +33.55% | +27.52% | N/A |
Revenue CAGR (FY2023 to FY2025) | 30.50% |
|
|
|
EBITDA (excl. Exceptional Items) | 13,544.29 | 22,470.70 | 17,766.03 | 13,307.63 |
EBITDA Margin (excl. Exceptional) % | 28.74% | 27.26% | 28.79% | 27.50% |
EBITDA CAGR (FY2023 to FY2025) | 29.94% |
|
|
|
Exceptional Items | (132.78) | 139.53 | (1,796.27) | (1,025.28) |
Profit Before Tax | 7,619.84 | 12,423.14 | 7,450.36 | 5,707.33 |
Total Tax Expense | 1,901.53 | 1,606.42 | 2,118.33 | 1,565.29 |
Profit After Tax (PAT, total) | 5,718.31 | 10,816.72 | 5,332.03 | 4,142.04 |
PAT (Rs. Crore) | Rs.571.8 Cr | Rs.1,081.7 Cr | Rs.533.2 Cr | Rs.414.2 Cr |
PAT Margin % | 12.13% | 13.12% | 8.64% | 8.56% |
Basic EPS (Rs., post-split/bonus) | 4.86 | 9.25 | 5.27 | 3.78 |
Return on Net Worth (RoNW) % | 8.72* | 18.16% | 14.75% | 12.70% |
Return on Capital Employed (ROCE) % | N/A | 26.98% | 27.74% | N/A |
Net Debt (incl. Leases) / Adj. EBITDA | 3.31x | 2.00x | 2.15x | 1.67x |
NAV per Share (Rs.) | 55.72 | 50.91 |
|
|
Hospitals (actual / pro forma) | 38 / 48 | 37 | 33 | 28 |
Licensed Beds (actual / pro forma) | 10,761 / 12,367 | 10,494 | 9,520 | 7,699 |
Occupancy % | 65.31% | 67.09% | 65.32% | 63.47% |
ARPOB (Rs. per day) | 70,778.07 | 63,312.23 | 61,741.68 | 58,864.75 |
Average Length of Stay (days) | 2.73 | 2.88 | 2.93 | 2.85 |
Revenue grew from Rs.48,396.10 million (FY2023) to Rs.82,422.50 million (FY2025), a 30.50% CAGR, which the CRISIL Report identifies as the highest revenue growth among major private hospital players over that period.
Growth was broad-based: inpatient volumes grew from 278,212 (FY2023) to 439,724 (FY2025), occupancy improved from 63.47% to 67.09%, and Average Revenue per Occupied Bed (ARPOB) rose from Rs.58,864.75 to Rs.63,312.23 per day, reflecting an increasing mix of high-acuity CONGO-R specialties (up from 60.25% to 62.56% of gross inpatient revenue over the same window). EBITDA (excluding exceptional items) grew at a 29.94% CAGR, roughly tracking revenue, with margins holding in a stable 27.50% to 28.79% band.
Headline PAT growth (a 61.60% CAGR from FY2023 to FY2025) overstates the underlying improvement, however: FY2024 PAT was depressed by Rs.1,796.27 million of exceptional items, including a Rs.1,140.65 million goodwill impairment, while FY2025 benefited from a small exceptional credit (Rs.139.53 million) and, more materially, a large one-time deferred tax credit (part of a Rs.1,300.73 million net deferred tax benefit that year).
Stripping out these swings, EBITDA growth of 29.94% is a fairer proxy for underlying operating momentum than the PAT CAGR. Return on Net Worth also tells a more measured story than the PAT figures alone: it rose from 12.70% (FY2023) to 18.16% (FY2025), the highest among the peer set in Section 5, before registering 8.72% (H1 FY2026, not annualised) on a much larger post-Fresh-Issue-related equity base following capital raised in FY2025 (Rs.7,499.99 million from an issue of equity shares) and the ongoing Sahyadri integration.
Balance Sheet and Cash Flow
Item | Sep 2025 (Rs. Mn) | FY2025 (Rs. Mn) | FY2024 (Rs. Mn) | FY2023 (Rs. Mn) |
Total Assets | 204,440.75 | 140,720.80 | 108,188.28 | 79,367.83 |
Total Equity | 65,823.79 | 60,001.76 | 40,875.10 | 35,138.44 |
Non-Current Borrowings | 97,703.43 | 44,699.81 | 37,001.37 | 19,483.48 |
Goodwill | 33,990.19 | 33,990.19 | 27,595.43 | 16,501.54 |
Cash and Cash Equivalents | 54,461.83 | 2,912.79 | 3,608.78 | 681.95 |
Trade Receivables | 7,846.92 | 6,373.01 | 4,588.80 | 3,168.35 |
Net Cash from Operating Activities | 9,420.89 | 15,698.30 | 13,886.45 | 11,520.55 |
Net Cash from Investing Activities | (8,778.30) | (26,583.39) | (8,704.95) | (9,952.48) |
Net Cash from Financing Activities | 50,906.45 | 9,040.82 | (2,502.09) | (1,451.38) |
The balance sheet shows a business that scaled quickly and recently took on significant new leverage: non-current borrowings roughly doubled in just six months, from Rs.44,699.81 million (FY2025 year-end) to Rs.97,703.43 million (September 2025), driven almost entirely by the Rs.53,100 million bridge NCD issuance used to fund the Sahyadri Acquisition (see Section 3).
This shows up directly in the leverage ratio: Net Debt (including lease liabilities) to Adjusted EBITDA jumped from 2.00x (FY2025) to 3.31x (H1 FY2026), a meaningful increase in financial risk that this IPO's Fresh Issue is specifically designed to reverse once the Rs.53,780 million Object 1 repayment is completed. Cash and cash equivalents correspondingly spiked to Rs.54,461.83 million as of September 30, 2025, almost entirely representing the undeployed NCD proceeds sitting ahead of the acquisition completion and planned IPO-funded repayment, rather than organic cash generation.
Operating cash flow has been consistently strong and positive throughout, from Rs.11,520.55 million (FY2023) to Rs.15,698.30 million (FY2025), supported by a negative working capital cycle (negative 16 days in FY2025, negative 12 days in H1 FY2026) driven by the company's high cash and insurance/TPA payor mix (86.59% of gross inpatient revenue in FY2025), a genuine structural strength for a hospital business of this scale.
How Does It Compare to Peers?
The DRHP discloses three listed industry peers: Apollo Hospitals Enterprise Limited, Fortis Healthcare Limited, and Max Healthcare Institute Limited. Figures below are FY2025; P/E for peers is based on closing market price on NSE as of March 20, 2026 divided by Diluted EPS.
Company | Revenue FY25 (Rs. Mn) | EPS (Rs.) | P/E (x) | RoNW (%) | NAV/Share (Rs.) |
Manipal Health Enterprises Limited (Our Company) | 82,422.50 | 9.25 | [TBD] | 18.16% | 50.91 |
Apollo Hospitals Enterprise Ltd. | 2,17,940.00 | 100.56 | 73.23 | 17.61% | 571.15 |
Fortis Healthcare Ltd. | 77,827.52 | 10.26 | 80.12 | 8.68% | 118.11 |
Max Healthcare Institute Ltd. | 86,670.00 | 11.07 | 87.63 | 11.47% | 96.50 |
Manipal's FY2025 Return on Net Worth of 18.16% is the highest among all four companies shown, ahead of Apollo Hospitals' 17.61%, Max Healthcare's 11.47%, and Fortis Healthcare's 8.68%, a genuinely strong result for a company that also carries a smaller revenue base than Apollo (which at Rs.2,17,940.00 million is roughly 2.6 times Manipal's revenue) and is comparable in scale to Fortis and Max Healthcare.
Manipal's NAV per share (Rs.50.91) is the lowest of the four in absolute rupee terms, though this reflects its much lower face value (Rs.2 versus Rs.5 for Apollo and Rs.10 for Fortis and Max Healthcare) rather than a smaller equity base per se; investors should compare on a like-for-like, per-rupee-of-face-value basis rather than the raw NAV figure.
The industry P/E range is comparatively tight (73.23x to 87.63x, average 80.33x) relative to some other sectors in this report series, reflecting the sector's consistently high growth expectations across all four companies. Since the Offer Price and hence Manipal's own P/E remain undetermined ([TBD]), valuation attractiveness relative to peers cannot yet be assessed, but Manipal's combination of the highest revenue growth (per the CRISIL Report) and the highest RoNW in the peer set is a favourable starting point.
Key Risks
l Leverage increased sharply in H1 FY2026 due to the Sahyadri Acquisition: Net Debt (including lease liabilities) to Adjusted EBITDA rose from 2.00x (FY2025) to 3.31x (September 2025), following a Rs.53,100 million bridge NCD issuance by subsidiary MHPL. Nearly three-quarters of the Rs.80,000 million Fresh Issue (Objects 1 and 2, totalling Rs.59,520 million) is earmarked to repay this acquisition debt and complete the buyout, meaning the growth story here is closely intertwined with successfully digesting a single, very recent, large acquisition.
l The Sahyadri Group acquisition (10 hospitals, 1,606 licensed beds in Maharashtra) was completed only in October to December 2025, mere months before this DRHP, and integration is explicitly ongoing: standardising clinical protocols, obtaining or renewing licenses and TPA/insurance contracts in the acquired entities' names, and rebranding. The company's own risk factors flag potential delays, unforeseen liabilities, and failure to realise expected synergies as real possibilities.
l Reported PAT growth overstates underlying operating improvement: FY2024 PAT was depressed by Rs.1,796.27 million of exceptional items (including a Rs.1,140.65 million goodwill impairment), while FY2025 benefited from an exceptional credit and a large one-time deferred tax credit. The cleaner EBITDA (excluding exceptional items) CAGR of 29.94% (FY2023 to FY2025) is a more representative growth figure than the 61.60% PAT CAGR.
l A related-party conflict exists within the underwriting syndicate: DBS Bank India Limited is a named Book Running Lead Manager to this Offer, while its parent, DBS Bank Limited, is one of five debenture holders being repaid Rs.53,780 million directly from this IPO's Fresh Issue proceeds. DBS Bank India Limited has been restricted to a marketing-only role under SEBI conflict-of-interest regulations, a disclosed and regulated arrangement, but one worth investor awareness given the scale of the repayment involved.
l Revenue remains meaningfully concentrated in Karnataka, contributing 49.55% of revenue (H1 FY2026, actual basis; 43.96% pro forma) and as high as 66.61% in FY2023; while this concentration has declined steadily as the company has diversified into Eastern India and, most recently, Maharashtra via Sahyadri, any regional disruption in Karnataka would still disproportionately affect results.
l The company derives 64.08% of gross inpatient revenue (H1 FY2026) from CONGO-R (Cardiac, Oncology, Neuro, Gastro, Orthopedic and Renal) specialties; any shift in patient preferences, doctor availability, or competitive dynamics specific to these high-acuity specialties would disproportionately affect the business.
l Six hospitals in the network are operated under Operate and Manage (O&M) agreements with third-party trusts (Human Care Medical Charitable Trust, Eastern India Health Foundation, and Konkan Mitra Mandal Medical Trust) rather than owned outright, creating dependence on the terms and renewal of those agreements.
l The final tranche of the Sahyadri minority stake acquisition carries a variable cost: the base consideration of Rs.5,740.51 million could rise to as much as Rs.6,956.79 million if the Sahyadri Group's trailing twelve-month EBITDA reaches Rs.4,000 million before the transaction completes, with any excess funded from internal accruals rather than the Fresh Issue.
l Healthcare businesses inherently carry litigation and regulatory exposure, including claims of alleged medical negligence and regulatory actions arising from the provision of healthcare services, an industry-wide risk rather than one specific to this company.
l A possible Pre-IPO Placement of up to Rs.16,000 million, the largest such figure in this report series, could reduce the Fresh Issue size and change the final Net Proceeds available for the disclosed Objects of the Offer.
l The Offer for Sale spans seven Selling Shareholders exiting at Weighted Average Costs of Acquisition ranging from Rs.68.73 to Rs.355.66 per share, reflecting more than a decade of private equity and venture ownership; the scale and breadth of this exit is a signal worth weighing alongside the company's own growth narrative.
l The General Corporate Purposes allocation is capped only as a percentage (25% of Gross Proceeds) rather than disclosed as an absolute amount, leaving a portion of Fresh Issue proceeds subject to management discretion at the time of listing.
Positives to Note
l India's largest multispecialty hospital network by bed capacity (12,367 licensed beds, pro forma) and second-largest by hospital count, with the widest geographic footprint among private hospital chains (14 states and union territories) and the only private chain leading simultaneously in three major metros: Bengaluru, Kolkata, and Pune.
l Highest Return on Net Worth among all disclosed peers: 18.16% (FY2025) versus Apollo Hospitals' 17.61%, Max Healthcare's 11.47%, and Fortis Healthcare's 8.68%, alongside the highest revenue growth among major private hospital players over FY2023 to FY2025, per the CRISIL Report.
l Negative working capital cycle (16 days in FY2025, 12 days in H1 FY2026): the company collects cash from patients and insurers faster than it pays suppliers, a genuine structural strength supported by an 86.59% cash and insurance/TPA payor mix (FY2025), and consistently strong, positive operating cash flow every period shown (Rs.11,520.55 million to Rs.15,698.30 million, FY2023 to FY2025).
l Proven, repeatable acquisition playbook: the leading consolidator among private hospital chains in India since Fiscal 2021 by beds added through acquisition, with demonstrated post-acquisition improvement (for example, Columbia Asia's EBITDA margin improved from 27.41% to 31.95% between FY2023 and FY2025 following its earlier acquisition).
l Improving operational efficiency alongside a rising-acuity mix: Average Length of Stay held broadly steady between 2.85 and 2.93 days (FY2023 to FY2025) and declined to 2.73 days in H1 FY2026, the lowest among major hospital peers per the CRISIL Report, even as the CONGO-R high-acuity specialty mix increased.
l Deep-rooted brand and legacy: founded on the Pai family's multi-generational history in medical education and healthcare (Kasturba Medical College, one of India's first private medical colleges), with the flagship Bengaluru hospital rated the number one hospital in the city for 20 consecutive years (2005 to 2025), and backing from marquee global institutional investors including Temasek, TPG, and Novo Holdings.
l Declining regional concentration reflecting successful diversification: Karnataka's share of revenue fell steadily from 66.61% (FY2023) to 49.55% (H1 FY2026, actual basis), as the network expanded into Eastern India and, most recently, Maharashtra, reducing single-region dependence over time.
Disclaimer
The content on this website is for informational and educational purposes only and should not be construed as investment advice, a recommendation, or a solicitation to buy or sell any security, mutual fund, or financial instrument. Equity Research India is not a SEBI-registered investment advisor or research analyst, and nothing on this site constitutes personalized financial advice.
Mutual fund investments are subject to market risks. Please read all scheme-related documents carefully before investing. Past performance is not indicative of future returns. NAV, returns, rankings, and other data may change and may not reflect the most current information at the time of reading.
Readers should conduct their own due diligence and consult a SEBI-registered financial advisor before making any investment decisions. Equity Research India and its authors accept no liability for any loss or damage arising from the use of this content.